SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 1417.
  • 2
    Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 110510.
  • 3
    Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 11256.
  • 4
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 5
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594602.
  • 6
    Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 7639.
  • 7
    Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J Rheumatol 2001; 28: 3602.
  • 8
    Woo P. Nomenclature and classification of arthritis in children. In: MuntheE, editor. The care of rheumatic children: EULAR bulletin no. 3. Basle (Switzerland): EULAR Publishers; 1978. p. 4750.
  • 9
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1996; 8: 44954.
  • 10
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 11
    Ranza R, Marchesoni A, Calori G, Bianchi G, Braga M, Canazza S, et al. The Italian version of the functional disability index of the Health Assessment Questionnaire: a reliable instrument for multicenter studies on rheumatoid arthritis. Clin Exp Rheumatol 1993; 11: 1238.
  • 12
    Ware JE Jr, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: Health Institute; 1994.
  • 13
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 14
    Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumor necrosis factor-α (cA2). Br J Rheumatol 1997; 36: 58993.
  • 15
    Kimura Y, Imundo LF, Li SC. High dose infliximab in the treatment of resistant systemic juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S272.
  • 16
    Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59: 134159.
  • 17
    Honkanen VE, Tynjala P, Vahasalo P, Lahdenne P. Infliximab in juvenile arthritis: 1-year follow-up [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S480.
  • 18
    Masatlioglu S, Gogus F, Cevirgen D, Seyahi E, Hatemi G, Ozdogan H. Infliximab in the treatment of refractory juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2002; 46 Suppl 9: S481.